Showing results (351-360 of 415) with videos related to
Sort By:
Pageof 42
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 21, 2006
Graft-versus-host reactions and the effectiveness of donor lymphocyte infusionsCarol Ann Huff, Ephraim J Fuchs, B Douglas Smith, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 6, 2010
K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylateB Douglas Smith, Yvette L Kasamon, Jeanne Kowalski, et al.Leukemia Research|September 17, 2025
Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbiditiesJ Preston Claiborne, Daniel Li, Hua-Ling Tsai, et al.Leukemia Research|September 14, 2016
Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studiesKelly J Norsworthy, Eunpi Cho, Jyoti Arora, et al.Journal of Translational Medicine|July 12, 2017
Impaired B cell immunity in acute myeloid leukemia patients after chemotherapyMeghali Goswami, Gabrielle Prince, Angelique Biancotto, et al.Blood Neoplasia|September 15, 2025
Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AMLAndrew D Zale, Venkata Preetam Sandeep Kaduluri, Jonathan A Webster, et al.Leukemia & Lymphoma|July 28, 2012
Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemiaYvette L Kasamon, Robert A Brodsky, Michael J Borowitz, et al.Leukemia Research|July 6, 2010
Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSFB Douglas Smith, Richard J Jones, Eunpi Cho, et al.Cancer Research|October 15, 2009
Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignanciesYing Ye, Michael A McDevitt, Mingzhou Guo, et al.American Journal of Hematology|August 4, 2018
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study resultsJorge E Cortes, B Douglas Smith, Eunice S Wang, et al.Pageof 42